Market Overview
Market Size and Outlook
- The global multi cancer early detection (MCED) test market was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.5 billion in 2026 to USD 5.3 billion by 2035, expanding at a CAGR of 14.8%.
- The multi cancer early detection test market grew from USD 700 million in 2022 to USD 1.1 billion in 2024, registering a historical growth rate of 18.7%.
- The gene panel, LDT, and others segment was valued at USD 1.2 billion in 2025 and held a dominant market share of around 91.9%.
- The hospitals segment held a leading market share of 48.7% in 2025.
Demand and Growth Drivers
- WHO data indicate the number of new cancer cases per year is projected to reach around 35 million by 2050 from 20 million cases in 2022, a rise of over 77%.
- The MCED test offers a minimally invasive method of detecting many types of cancers using a single blood sample.
- Technological advancements in data analytics and artificial intelligence (AI) significantly enhance the accuracy, speed, and efficiency of cancer screening procedures.
Analyst Perspective
- Brevintel analysis indicates growing adoption of liquid biopsy technologies, expansion of precision medicine approaches, and rising focus on preventive healthcare and population screening are among the key trends shaping market growth.
- The North America region accounted for 42.3% of the market in 2025, driven by the region’s advanced healthcare infrastructure and technological advancements.
Market Dynamics
Drivers, Restraints, and Opportunities
- The increasing prevalence of cancer, advancements in data analytics and artificial intelligence (AI) utilized in cancer screening, and a high cancer detection rate are driving steady growth.
- Companies are investing significantly in biomarker discovery, next-generation sequencing technologies, artificial intelligence-driven analytics, and large-scale clinical validation studies.
- The market is witnessing increasing efforts to secure regulatory approvals and reimbursement support, as these factors are critical for large-scale adoption.
Segmentation Analysis
Type and Biomarker Outlook
- The gene panel, LDT, and others segment was valued at USD 1.2 billion in 2025 and held a dominant market share of around 91.9%.
- The cfDNA methylation analysis segment was valued at USD 549.8 million in 2025.
End Use Outlook
- The hospitals segment held a leading market share of 48.7% in 2025.
Regional Outlook
North America, Europe, and Asia Pacific
- The North America region accounted for 42.3% of the market in 2025.
- Europe multi cancer early detection (MCED) test industry accounted for USD 350.3 million in 2025.
- The Asia Pacific region is projected to show a lucrative growth of about 16.1% during the forecast period.
Competitive Landscape
Overview
- The major players in the global market are GRAIL, EXACT SCIENCES CORPORATION, Guardant Health, Guangzhou AnchorDx Medical, and Genecast Biotechnology.
- Exact Sciences emphasizes strengthening its cancer detection portfolio through continuous biomarker research, product innovation, and expanding access to non-invasive screening solutions.
- Guangzhou AnchorDx Medical focuses on developing proprietary genomic and methylation-based technologies.
Key Players
Integrated Producers
- GRAIL
- EXACT SCIENCES CORPORATION
- GUARDANT HEALTH
- Guangzhou AnchorDx Medical
- Genecast Biotechnology
Specialty Suppliers
- AnPac Bio-Medical Science
- Burning Rock Biotech
- EarlyDiagnostics
- Elypta
- Freenome Holdings
- Harbinger Health
- Micronoma
- SeekIn
- Singlera Genomics